Saudi Press

Saudi Arabia and the world
Thursday, Oct 02, 2025

Coronavirus FAQs: Can I Drink Between Vaccine Doses? What Is 'Vaccine Efficacy'?

Coronavirus FAQs: Can I Drink Between Vaccine Doses? What Is 'Vaccine Efficacy'?

People who've had dose 1 are wondering ... can I have a few drinks before dose 2 or will that muck things up? Also: Do you really understand the concept of "vaccine efficacy"? It's complicated!
I have started hearing that vaccine recipients should abstain from alcohol between the first and second doses of the COVID vaccine. Is this a thing?


It's true that chronic, heavy drinking and binge drinking can suppress your immune system, Kennedy says. And there are plenty of health reasons not to drink alcohol, he adds. But an occasional drink here and there — including a celebratory toast after your second shot? "That won't have an effect," he says.

What, exactly, does it mean that a vaccine is, for example, 92% efficacious? Does it mean there's an 8% chance of my getting COVID-19? If so, why would anyone want to get a vaccine that's only 60 or 65% efficacious?


I find the subject of vaccine efficacy very confusing!


Don't worry: If you find it confusing, you're probably on the right track! Efficacy rates (and effectiveness rates and point estimates and confidence intervals) should appear at least a little confusing to most non-biostatisticians. The concepts rely on statistical thinking that many aren't familiar with, says Brianne Barker, a virologist at Drew University.

The tendency to oversimplify has led many people to the same — mistaken — conclusion that an efficacy rate of 92 percent would mean that of 100 vaccinated people, 8 of them would get sick during a pandemic.

But that's not the case. Fortunately, a vaccine with a 92 percent efficacy rate actually means your chances of getting the disease is much, much less than 8 percent. It means that if you were exposed to the disease, your chances of getting infected would be 92 percent less if you were vaccinated than if you weren't.

If you want to geek out on the exact math on how much your chances of getting COVID drops after a vaccine, you'd have to know what the probability of getting sick is, Barker says. "And that varies based on the population that you look at."

Say you originally had a 10% chance of getting sick without being vaccinated. If you got that vaccine with an efficacy rate of 92%, your chance of getting sick would drop from 10% to less than 1% — 0.8%, to be exact.

In reality, the trials found that the probability of getting sick in the placebo groups was much less than 10%. In the Pfizer trial, for example, it was 0.79% — or less than one per 100 people. Participants who got the real vaccine had just a .04 percent chance of getting COVID ... that's 4 in 10,000 people.

While efficacy rates should, theoretically, make comparisons among different vaccines possible, a number of variables have made it more like "comparing an efficacy rate of 70 percent to purple," says Richard Kennedy, professor of medicine at the Mayo Clinic in Rochester, Minn., and co-director of the Vaccine Research Group.

"You're laughing because that's a ludicrous comparison," he says. But to truly make an apples-to-apples comparison, he says, you'd have to run the vaccines head-to-head in the same clinical trial. As it was, the characteristics of the participants in the various trials were different (Johnson & Johnson enrolled more people at higher risk, for example), variants were circulating during some trials and not others, and each trial defined the disease differently. (For example, Moderna defined a COVID-19 infection as a positive PCR test plus two symptoms from one group or one symptom from another group. Pfizer defined it as a positive PCR test plus one symptom.)

"The devil really is in the details," he says.

Can I get the Johnson & Johnson vaccine and then sign up for Pfizer or Moderna?


Theoretically, that should be fine, Barker and Kennedy agree. In real life, it's unlikely to happen — "it's hard enough to get one in the first place," Barker says, and "having already received one shot of Johnson & Johnson, you'd be considered fully vaccinated and probably no one is going to let you get another one because you're taking it away from someone who needs it," Kennedy says.

However, your body would likely handle the mixing and matching just fine, since all of the vaccines have the same antigen, Kennedy explains. The antigen is the component that your immune response recognizes — in this case, the spike protein. It's akin to the flu vaccine, he says. We get influenza vaccines every year, often with similar strains, without worrying about which company made it. When antigens are different, however, your body usually develops weaker antibodies.

"Another thing to consider is what will happen if we need booster doses in 6 months, 2 years, whenever," he says. "I doubt that we will have the resources or ability to only provide the same vaccine that you originally received."

And can people who have an allergic reaction to their first Pfizer or Moderna shot follow up with Johnson & Johnson?


Again, this may work in theory, Kennedy says, but until vaccines are more widely available it may not be possible. In the meantime, be reassured that your first dose may provide pretty good protection. After all, the Pfizer and Moderna vaccines weren't studied as single doses, so the efficacy rate after a month or two could be higher than you think, he points out.

Newsletter

Related Articles

Saudi Press
0:00
0:00
Close
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
Nvidia and Abu Dhabi’s TII Launch First AI-&-Robotics Lab in the Middle East
UK, Canada, and Australia Officially Recognise Palestine in Historic Shift
New Eye Drops Show Promise in Replacing Reading Glasses for Presbyopia
Dubai Property Boom Shows Strain as Flippers Get Buyer’s Remorse
Top AI Researchers Are Heading Back to China as U.S. Struggles to Keep Pace
JWST Data Brings TRAPPIST-1e Closer to Earth-Like Habitability
UAE-US Stargate Project Poised to Make Abu Dhabi a Global AI Powerhouse
Trump and Starmer Clash Over UK Recognition of Palestinian State Amid State Visit
Saudi Arabia cracks down on music ‘lounges’ after conservative backlash
Saudi Arabia Signs ‘Strategic Mutual Defence’ Pact with Pakistan, Marking First Arab State to Gain Indirect Access to Nuclear Strike Capabilities in the Region
Sam Altman sells the 'Wedding Estate' in Hawaii for 49 million dollars
Turkish car manufacturer Togg Enters German Market with 5-Star Electric Sedan and SUV to Challenge European EV Brands
World’s Longest Direct Flight China Eastern to Launch 29-Hour Shanghai–Buenos Aires Direct Flight via Auckland in December
New OpenAI Study Finds Majority of ChatGPT Use Is Personal, Not Professional
Kuwait opens bidding for construction of three cities to ease housing crunch.
This Week in AI: Meta’s Superintelligence Push, xAI’s Ten Billion-Dollar Raise, Genesis AI’s Robotics Ambitions, Microsoft Restructuring, Amazon’s Million-Robot Milestone, and Google’s AlphaGenome Update
Indian Student Engineers Propose “Project REBIRTH” to Protect Aircraft from Crashes Using AI, Airbags and Smart Materials
Could AI Nursing Robots Help Healthcare Staffing Shortages?
Turkish authorities seize leading broadcaster amid fraud and tax investigation
Qatari prime minister says Netanyahu ‘killed any hope’ for Israeli hostages
Apple Introduces Ultra-Thin iPhone Air, Enhanced 17 Series and New Health-Focused Wearables
Big Oil Slashes Jobs and Investments Amid Prolonged Low Crude Prices
Social Media Access Curtailed in Turkey After CHP Calls for Rallies Following Police Blockade of Istanbul Headquarters
Did the Houthis disrupt the internet in the Middle East? Submarine cables cut in the Red Sea
Gold Could Reach Nearly $5,000 if Fed Independence Is Undermined, Goldman Sachs Warns
Uruguay, Colombia and Paraguay Secure Places at 2026 World Cup
Trump Administration Advances Plans to Rebrand Pentagon as Department of War Instead of the Fake Term Department of Defense
Tether Expands into Gold Sector with Profit-Driven Diversification
Trump’s New War – and the ‘Drug Tyrant’ Fearing Invasion: ‘1,200 Missiles Aimed at Us’
At the Parade in China: Laser Weapons, 'Eagle Strike,' and a Missile Capable of 'Striking Anywhere in the World'
Information Warfare in the Age of AI: How Language Models Become Targets and Tools
Israeli Airstrike in Yemen Kills Houthi Prime Minister
After the Shock of Defeat, Iranians Yearn for Change
YouTube Altered Content by Artificial Intelligence – Without Permission
Iran Faces Escalating Water Crisis as Protests Spread
More Than Half a Million Evacuated as Typhoon Kajiki Heads for Vietnam
HSBC Switzerland Ends Relationships with Over 1,000 Clients from Saudi Arabia, Lebanon, Qatar, and Egypt
Sharia Law Made Legally Binding in Austria Despite Warnings Over 'Incompatible' Values
Dogfights in the Skies: Airbus on Track to Overtake Boeing and Claim Aviation Supremacy
Tim Cook Promises an AI Revolution at Apple: "One of the Most Significant Technologies of Our Generation"
Are AI Data Centres the Infrastructure of the Future or the Next Crisis?
Miles Worth Billions: How Airlines Generate Huge Profits
Zelenskyy Returns to White House Flanked by European Allies as Trump Pressures Land-Swap Deal with Putin
Beijing is moving into gold and other assets, diversifying away from the dollar
Cristiano Ronaldo Makes Surprise Stop at New Hong Kong Museum
Zelenskyy to Visit Washington after Trump–Putin Summit Yields No Agreement
×